SCM
DICE

Suvretta Capital Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Suvretta Capital Management’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-410,000
Closed -$10.4M – 109
2021
Q4 		$10.4M Hold
410,000
– – 0.2% 62
2021
Q3 		$13.4M Buy
+410,000
New +$14M 0.23% 56

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Suvretta Capital Management's DICE Position: Q1 2022 in Review

Suvretta Capital Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q1 2022, closing a stake of 410,000 shares — an estimated $10.4M sold.

Suvretta Capital Management first reported a position in DICE in Q3 2021 and held it in 2 quarters. The position peaked at $13.4M in Q3 2021. 76 funds tracked by Wall St. Rank hold DICE as of Q1 2022.

  • Suvretta Capital Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 410,000 DICE Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $10.4M.
  • Suvretta Capital Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Suvretta Capital Management's DICE Therapeutics, Inc. Common Stock position peaked at $13.4M in Q3 2021.
  • 76 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Suvretta Capital Management's 13F filing for Q1 2022, filed 16 May 2022.